Abbott reports higher sensitivity of new whole‑genome Oncodetect test for colorectal cancer recurrence
Abbott presented results from the Beta‑CORRECT study at the ESMO 2026 Congress showing its whole‑genome sequencing‑based Oncodetect MRD assay detected colorectal cancer recurrence with 72.2% sensitivity within two years after surgery, versus 42.2% for the earlier whole‑exome version. The trial involved 279 post‑surgical patients, mainly stage II and III, and identified additional ctDNA cases at very low concentrations. Detectable ctDNA after surgery was linked to a 10.6‑fold higher risk of recurrence and markedly lower two‑year disease‑free survival. The test is not yet FDA‑cleared and is performed at a CLIA‑certified lab.
Why it matters
The company says the improved detection rate could broaden the clinical use of the assay and drive revenue growth, but investors should consider that regulatory approval is still pending ().
Key facts
- 1The whole‑genome Oncodetect test showed 72.2% sensitivity for recurrence within two years after surgery. prnewswire.com
- 2The earlier whole‑exome version recorded 42.2% sensitivity for the same endpoint. investing.com
- 3The Beta‑CORRECT study evaluated post‑surgical samples from 279 patients, primarily stage II and III colorectal cancer. prnewswire.com
- 4Among 157 patients tested with both assays, the whole‑genome test found ctDNA in all 29 cases identified by the whole‑exome test and an extra 15 cases. investing.com
- 5Patients with detectable ctDNA after surgery faced a 10.6‑fold higher recurrence risk compared with ctDNA‑negative patients. prnewswire.com
- 6Two‑year disease‑free survival was 36.2% for ctDNA‑positive patients versus 92.3% for ctDNA‑negative patients. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.